“Non-Celiac Gluten Sensitivity: What It Is and How It Differs from Celiac”

The Rise of Gluten Sensitivity

In the past 15 years, gluten-free diets have expanded dramatically beyond the celiac disease community. Surveys suggest that as many as 1 in 3 Americans actively limit or avoid gluten, most of whom have no diagnosis of celiac disease or wheat allergy. Many of these people report that gluten makes them feel worse: bloating, abdominal pain, fatigue, brain fog, headaches, and joint pain that improve when wheat is removed from the diet.

Whether this represents a real and distinct medical condition, a variation of irritable bowel syndrome, a response to non-gluten wheat components, or some combination of these has been debated intensely in gastroenterology research. The science has become clearer in the past decade, and the honest answer is: non-celiac gluten sensitivity exists as a clinical entity, but it is less common, less well-defined, and more heterogeneous than it is often portrayed [1].

What NCGS Actually Is

Non-celiac gluten sensitivity (NCGS) is defined as a condition where ingestion of gluten causes symptoms in individuals who do not have celiac disease (confirmed by negative celiac serology and/or normal intestinal biopsy) and do not have IgE-mediated wheat allergy [2]. The definition is, by design, a diagnosis of exclusion.

Proposed diagnostic criteria (the Salerno Expert Criteria) require that symptoms are triggered by gluten ingestion and that this relationship is confirmed by a double-blind, placebo-controlled gluten challenge: the patient consumes either capsules containing gluten or capsules containing a placebo (like rice flour) without knowing which they are receiving, and their symptom pattern is compared between the two conditions [3].

When this rigorous testing has been applied in research settings, the proportion of people who actually have reproducible responses specifically to gluten is lower than the proportion who believe they do. One influential study found that about 8% of people who identified as gluten-sensitive showed a true response to gluten on blinded challenge [4]. The others had symptoms influenced by nocebo effects (expecting to feel bad) or by other components of wheat.

Is It Gluten or Something Else in Wheat?

This is where the science gets genuinely interesting. Wheat contains many different components beyond gluten, and at least two others may be important drivers of symptoms in people who react to wheat:

Fructans (FODMAPs)

Wheat is one of the primary dietary sources of fructans, a type of fermentable oligosaccharide that falls under the FODMAP umbrella. Fructans are not absorbed in the small intestine; they pass to the colon, where bacteria ferment them, producing gas and triggering fluid shifts that cause bloating, distension, abdominal pain, altered bowel habits, and discomfort. These are classic IBS symptoms.

A well-designed randomized controlled trial by Biesiekierski et al. compared participants consuming gluten, fructans, or placebo in a crossover design. Gastrointestinal symptoms were significantly higher when participants consumed fructans, compared to gluten, which did not significantly worsen GI symptoms versus placebo [5]. This suggests that in many people who attribute their wheat sensitivity to gluten, the actual culprit may be the fermentable carbohydrate content of wheat rather than gluten protein.

Amylase-Trypsin Inhibitors (ATIs)

ATIs are proteins found in wheat that activate innate immune receptors (specifically Toll-like receptor 4) in intestinal immune cells, triggering inflammation. They are present in gluten-containing grains and have been implicated in triggering intestinal and systemic immune activation in people with and without celiac disease. ATIs may explain why some patients with conditions like non-alcoholic fatty liver disease, multiple sclerosis, or inflammatory bowel disease report improvements on a gluten-free diet that are not mediated by gluten per se [6].

Weak Opioid Activity of Gluten Peptides

Some gluten-derived peptides (called gliadorphins or gluteomorphins) have weak opioid-like activity. The relevance of this to NCGS symptoms is speculative, but it has generated interest in the context of neurological and behavioral symptoms reported by some NCGS patients.

How NCGS Differs From Celiac Disease

Understanding the differences between NCGS and celiac disease is not merely academic; it has direct implications for how strictly the gluten-free diet needs to be followed and what monitoring is required.

Mechanism

Celiac disease is a specific autoimmune condition. In genetically susceptible individuals (those carrying HLA-DQ2 or HLA-DQ8), gluten peptides trigger an adaptive immune response: T cells are activated, antibodies are produced (including anti-tTG antibodies), and the intestinal lining is progressively destroyed. The mechanism is well-characterized.

NCGS does not follow this autoimmune pathway. There is no HLA genetic predisposition (or the association is much weaker), no anti-tTG antibodies, and no villous atrophy. The immune mechanisms involved are less clear, but appear to involve innate immune activation rather than adaptive immune response. Some NCGS patients have elevated anti-gliadin antibodies (not anti-tTG antibodies), and some show markers of increased intestinal permeability, but the findings are inconsistent across studies [7].

Intestinal Damage

This is the most clinically significant difference. Celiac disease causes structural damage to the small intestinal mucosa: villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes. This damage is responsible for malabsorption of nutrients and drives long-term complications. NCGS, by definition, does not cause villous atrophy. Intestinal biopsies in NCGS patients are either normal or show only mildly increased intraepithelial lymphocytes (Marsh 1), a nonspecific finding seen in many conditions [8].

This distinction means that NCGS does not carry the same risks as celiac disease for nutrient deficiency (iron, B12, folate, vitamin D), bone loss, infertility, and intestinal lymphoma that stem from mucosal damage.

Diagnostic Markers

Celiac disease has reliable serological markers: tTG-IgA, endomysial antibody (EMA), and deamidated gliadin peptide antibodies (DGP-IgA/IgG) are elevated in active disease and normalize on the gluten-free diet. NCGS has no validated biomarker. There is no blood test, stool test, or biopsy finding that confirms NCGS. Diagnosis rests entirely on the clinical pattern: ruling out celiac and wheat allergy, then documenting symptom improvement on gluten-free diet and symptom recurrence on gluten rechallenge.

HLA Genetics

Over 90% of celiac disease patients carry HLA-DQ2 or HLA-DQ8. Testing negative for both makes celiac disease very unlikely (though not impossible). In NCGS, HLA-DQ2 and HLA-DQ8 are not consistently overrepresented, meaning the genetic predisposition is different or absent.

Dietary Strictness Required

For celiac disease, strict, lifelong elimination of all gluten, including trace amounts from cross-contamination, is required to prevent ongoing intestinal damage. For NCGS, the threshold for symptom production appears to be higher, and the stakes of an imperfect diet are lower (no structural gut damage accrues). Some NCGS patients can tolerate small amounts of gluten without symptoms, and some appear to lose their sensitivity over time, particularly if their primary drivers are fructan intolerance or ATIs rather than gluten itself [9].

Symptoms: Overlapping but Distinct

The symptom profiles of NCGS and celiac disease overlap considerably: both can cause bloating, abdominal pain, diarrhea, fatigue, and brain fog. However, NCGS tends to show a higher prevalence of certain non-GI symptoms relative to celiac disease.

NCGS symptom profile:

• Gastrointestinal: bloating (the most common symptom), abdominal pain, diarrhea, nausea, altered bowel habits
• Neurological: brain fog, headaches, peripheral tingling (though less severe and progressive than gluten ataxia or gluten neuropathy in celiac)
• Systemic: fatigue, muscle pain, joint pain
• Behavioral: some case reports of ADHD-like symptoms in children improving on a gluten-free diet

Compared to celiac disease, NCGS patients less commonly present with weight loss, nutrient deficiencies, anemia, or bone loss, reflecting the absence of malabsorption.

The Diagnostic Sequence: Why Order Matters

One of the most common clinical errors is starting a gluten-free diet before completing celiac disease testing. This is a significant problem because a gluten-free diet causes tTG-IgA antibodies to fall toward normal and causes intestinal villi to heal. A patient who has been gluten-free for several months may test negative for celiac disease when they actually have it.

The correct sequence is:

1. While eating a normal gluten-containing diet (at least one to two slices of wheat bread per day for a minimum of 6 weeks), test for celiac disease: tTG-IgA and total IgA.
2. If celiac serology is positive, proceed to upper endoscopy with small bowel biopsy for confirmation.
3. If celiac serology is negative and wheat allergy has been excluded (skin prick test or specific IgE to wheat), and symptoms respond to gluten elimination and recur with gluten reintroduction, the clinical diagnosis of NCGS can be considered.
4. Ideally, a blinded gluten challenge (as described in the Salerno criteria) is performed for formal confirmation, though this is rarely done outside research settings.

If a patient has already started a gluten-free diet before testing, a formal gluten challenge (reintroducing gluten for 6-8 weeks before testing) is necessary to properly rule out celiac disease. This is uncomfortable but important, particularly since the long-term management differs significantly between the two conditions.

The IBS Overlap

A substantial proportion of people who self-identify as gluten-sensitive actually have irritable bowel syndrome with a wheat sensitivity driven by fructans rather than gluten. The symptom profiles are similar, and wheat elimination relieves fructan-driven IBS symptoms just as it would relieve gluten-driven NCGS. The distinction matters for dietary management: if the culprit is fructans, a low-FODMAP diet (which reduces fructans from all sources, not just wheat) may be more appropriate than a gluten-free diet, and the patient does not need to avoid trace gluten contamination [10].

A practical approach for patients who react to wheat but test negative for celiac disease is a structured dietary trial: first a low-FODMAP diet to determine whether fructan restriction resolves symptoms, and then a careful reintroduction of gluten-containing foods that are low in fructans (sourdough bread made with a long fermentation process has reduced fructan content, for example). This approach can clarify whether wheat avoidance needs to be total or whether a more targeted low-FODMAP strategy is sufficient.

NCGS in the Clinic: What Current Evidence Supports

The field of NCGS is still maturing. The evidence base for NCGS as a discrete biological entity, separate from fructan intolerance and IBS, remains limited and contested. A 2022 systematic review concluded that there is currently insufficient evidence to confirm NCGS as a well-defined clinical condition with specific pathophysiological mechanisms, while acknowledging that a subset of patients clearly experience reproducible, gluten-specific responses [11].

For clinicians and patients, the practical approach is pragmatic: if symptoms consistently improve with gluten elimination and worsen with reintroduction, a trial of the gluten-free diet is reasonable, provided celiac disease has been properly ruled out first. The urgency and strictness of the diet are lower than for celiac disease, and regular reassessment of tolerance can be done over time.

Gut Healing and Regenerative Considerations

Even in the absence of celiac disease-level villous atrophy, NCGS and wheat sensitivity may involve intestinal permeability changes and low-grade mucosal inflammation. The gut-healing strategies relevant to celiac disease have some applicability here as well.

Supporting intestinal barrier integrity is a reasonable target. Zinc carnosine, a compound with specific evidence for supporting gastric and intestinal mucosal integrity, has been studied in the context of intestinal permeability and may be worth considering alongside dietary change [12]. Glutamine, the primary fuel for intestinal epithelial cells, supports mucosal repair and is often included in gut healing protocols. BPC-157 has shown intestinal barrier-protective effects in preclinical models and is used in regenerative medicine practices for patients with gut permeability issues, including those with wheat sensitivity and related conditions [13].

The microbiome picture in NCGS shares some features with that of celiac disease: altered microbial diversity and reduced relative abundance of beneficial Bifidobacterium and Lactobacillus species have been reported. Whether this is a driver or a consequence of NCGS is unknown, but supporting gut microbial health through prebiotic fiber (from vegetables, legumes, and gluten-free whole grains) and probiotic supplementation is a sensible adjunct to dietary change.

Summary: Key Differences at a Glance

• Autoimmune mechanism: Present in celiac disease; absent or different in NCGS
• Intestinal damage: Villous atrophy in celiac; normal or near-normal biopsy in NCGS
• Blood test markers: Elevated tTG-IgA, EMA in celiac; no validated markers in NCGS
• HLA genetics: Strongly linked to HLA-DQ2/DQ8 in celiac; weak or absent association in NCGS
• Nutrient deficiency risk: High in celiac (malabsorption from mucosal damage); low in NCGS
• Long-term complications: Significant (bone loss, lymphoma, autoimmune diseases) in celiac; not well-established in NCGS
• Dietary strictness required: Strict, lifelong, trace-amount avoidance for celiac; variable, often less strict for NCGS
• Prevalence: About 1% of population for celiac; estimated 0.5-6% for NCGS, though exact figures are uncertain

Related Reading

• Celiac Disease Symptoms: Beyond Digestive Issues
• Celiac Disease Treatment: Current Options and Emerging Therapies
• Celiac Disease Diet: The Complete Guide to Going Gluten-Free
• IBS Symptoms: What They Mean and What to Do
• Leaky Gut Symptoms: Separating Fact From Fiction

References

1. Catassi C, Elli L, Bonaz B, et al. Diagnosis of non-celiac gluten sensitivity (NCGS): the Salerno experts’ criteria. Nutrients. 2015;7(6):4966-4977. doi:10.3390/nu7064966. PMID: 26096570
2. Sapone A, Bai JC, Ciacci C, et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012;10:13. doi:10.1186/1741-7015-10-13. PMID: 22313950
3. Catassi C, Bai JC, Bonaz B, et al. Non-celiac gluten sensitivity: the new frontier of gluten related disorders. Nutrients. 2013;5(10):3839-3853. doi:10.3390/nu5103839. PMID: 24077239
4. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145(2):320-328. doi:10.1053/j.gastro.2013.04.051. PMID: 23648697
5. Skodje GI, Sarna VK, Minelle IH, et al. Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity. Gastroenterology. 2018;154(3):529-539. doi:10.1053/j.gastro.2017.10.040. PMID: 29102613
6. Zevallos VF, Raker V, Tenzer S, et al. Nutritional wheat amylase-trypsin inhibitors promote intestinal inflammation via activation of myeloid cells. Gastroenterology. 2017;152(5):1100-1113. doi:10.1053/j.gastro.2016.12.006. PMID: 27916547
7. Uhde M, Ajamian M, Caio G, et al. Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease. Gut. 2016;65(12):1930-1937. doi:10.1136/gutjnl-2016-311964. PMID: 27535020
8. Molina-Infante J, Santolaria S, Sanders DS, Fernandez-Banares F. Systematic review: noncoeliac gluten sensitivity. Aliment Pharmacol Ther. 2015;41(9):807-820. doi:10.1111/apt.13155. PMID: 25753138
9. Volta U, Bardella MT, Calabro A, Troncone R, Corazza GR. An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity. BMC Med. 2014;12:85. doi:10.1186/1741-7015-12-85. PMID: 24885375
10. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008;6(7):765-771. doi:10.1016/j.cgh.2008.02.058. PMID: 18456565
11. Dieterich W, Zopf Y. Gluten and FODMAPS: sense of a restriction/when is restriction necessary? Nutrients. 2019;11(8):1957. doi:10.3390/nu11081957. PMID: 31426398
12. Mahmood A, FitzGerald AJ, Marchbank T, et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007;56(2):168-175. doi:10.1136/gut.2006.099929. PMID: 16777920
13. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. doi:10.2174/138161211796197010. PMID: 21548867